These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27093238)

  • 1. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling.
    Namey E; Agot K; Ahmed K; Odhiambo J; Skhosana J; Guest G; Corneli A
    Cult Health Sex; 2016 Sep; 18(9):1081-91. PubMed ID: 27093238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa.
    Corneli AL; McKenna K; Headley J; Ahmed K; Odhiambo J; Skhosana J; Wang M; Agot K;
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19152. PubMed ID: 25224613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa.
    Matthews LT; Jaggernath M; Kriel Y; Smith PM; O'Neil K; Haberer JE; Hendrix C; Baeten JM; Ware NC; Wirth K; Psaros C; Bangsberg DR; Smit JA
    BMJ Open; 2019 Jul; 9(7):e027227. PubMed ID: 31350241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence.
    Haberer JE; Kidoguchi L; Heffron R; Mugo N; Bukusi E; Katabira E; Asiimwe S; Thomas KK; Celum C; Baeten JM
    J Int AIDS Soc; 2017 Jul; 20(1):21842. PubMed ID: 28741331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Pre-Exposure Prophylaxis-Stigma Paradox: Learning from Canada's First Wave of PrEP Users.
    Grace D; Jollimore J; MacPherson P; Strang MJP; Tan DHS
    AIDS Patient Care STDS; 2018 Jan; 32(1):24-30. PubMed ID: 29185801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa.
    Corneli A; Namey E; Ahmed K; Agot K; Skhosana J; Odhiambo J; Guest G
    AIDS Patient Care STDS; 2015 Sep; 29(9):503-9. PubMed ID: 26196411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Since both of us are using antiretrovirals, we have been supportive to each other": facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya.
    Patel RC; Stanford-Moore G; Odoyo J; Pyra M; Wakhungu I; Anand K; Bukusi EA; Baeten JM; Brown JM
    J Int AIDS Soc; 2016; 19(1):21134. PubMed ID: 27964776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
    Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B;
    AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial.
    Corneli A; Perry B; McKenna K; Agot K; Ahmed K; Taylor J; Malamatsho F; Odhiambo J; Skhosana J; Van Damme L
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):452-61. PubMed ID: 26536315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
    Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
    J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.
    Eakle R; Gomez GB; Naicker N; Bothma R; Mbogua J; Cabrera Escobar MA; Saayman E; Moorhouse M; Venter WDF; Rees H;
    PLoS Med; 2017 Nov; 14(11):e1002444. PubMed ID: 29161256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sexual risk context among the FEM-PrEP study population in Bondo, Kenya and Pretoria, South Africa.
    Headley J; Lemons A; Corneli A; Agot K; Ahmed K; Wang M; Odhiambo J; Skhosana J; Tharaldson J; Van Damme L; MacQueen K;
    PLoS One; 2014; 9(9):e106410. PubMed ID: 25229403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The informal use of antiretroviral medications for HIV prevention by men who have sex with men in South Florida: initiation, use practices, medications and motivations.
    Buttram ME
    Cult Health Sex; 2018 Nov; 20(11):1185-1198. PubMed ID: 29360420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceptions of HIV Preexposure Prophylaxis Among Young Pregnant Women from Rural KwaZulu-Natal, South Africa.
    Vazquez L; Moll AP; Kacin A; Ndlovu NE; Shenoi SV
    AIDS Patient Care STDS; 2019 May; 33(5):214-219. PubMed ID: 31067125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated with Use of Short-Term Pre-Exposure Prophylaxis for HIV Among Female Partners of Migrant Miners in Mozambique.
    Falcao J; Zerbe A; Lahuerta M; Baggaley R; Ahoua L; DiMattei P; Morales F; Ramiro I; El-Sadr WM
    AIDS Patient Care STDS; 2017 Dec; 31(12):528-534. PubMed ID: 29211515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City.
    Rael CT; Martinez M; Giguere R; Bockting W; MacCrate C; Mellman W; Valente P; Greene GJ; Sherman S; Footer KHA; D'Aquila RT; Carballo-Diéguez A
    AIDS Behav; 2018 Nov; 22(11):3627-3636. PubMed ID: 29589137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.
    Amico KR; Wallace M; Bekker LG; Roux S; Atujuna M; Sebastian E; Dye BJ; Elharrar V; Grant RM
    AIDS Behav; 2017 May; 21(5):1361-1375. PubMed ID: 27317411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
    Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN
    Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on biomedical HIV prevention options among women who inject drugs in Kenya.
    Bazzi AR; Yotebieng KA; Agot K; Rota G; Syvertsen JL
    AIDS Care; 2018 Mar; 30(3):343-346. PubMed ID: 28780885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.